Cargando…
Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
Direct oral anticoagulants (DOACs) have gained increasing popularity in clinical practice in the past decade. While DOACs have fewer associated adverse events as compared to warfarin, DOAC-induced hypersensitivity is a rare adverse event that has been reported in the literature. We describe a case o...
Autores principales: | Anis, Takla R, Jandreau, Whitney |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487854/ https://www.ncbi.nlm.nih.gov/pubmed/34616187 http://dx.doi.org/10.2147/CPAA.S325430 |
Ejemplares similares
-
The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014) -
Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020) -
Woman with pruritic rash and dermatographism
por: Malcolm, Trent R., et al.
Publicado: (2022) -
DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa
(Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022) -
Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)